Oura's CEO talks healthcare, but the real story behind wearable technology is data monetization and medical gatekeeping.
Global health security is on the chopping block. The WHO warns of systemic risk, but the hidden agenda behind these funding cuts exposes who truly benefits from fragile public health.
The hidden truth about medical research isn't the drug, it's the math. Unmasking the biostatisticians driving clinical trial outcomes.
The new Medicare drug price negotiation list isn't about saving seniors money; it’s a calculated political strike against Big Pharma.
Forget probiotics. The Algae4IBD conference signals a massive shift: seaweed is the next frontier in **Inflammatory Bowel Disease** treatment, and the real winners aren't the patients.
The WHO's new toolkit on scaling health innovations hides a harsh truth: this isn't about grassroots change. It’s about standardization for profit.
Digital microfluidic technology is changing 3D cell culture, but the real story is the centralization of pharmaceutical power it enables.
Is modern, metric-driven science sacrificing accidental breakthroughs? The death of **scientific serendipity** impacts innovation and funding strategy.
Are men being misled over testosterone replacement therapy (TRT)? The science suggests a billion-dollar industry is preying on natural aging.
New research pairs a cannabis compound with an anti-inflammatory, signaling a massive shift in Alzheimer’s prevention strategy.
The gut-brain axis link to Alzheimer's is confirmed, but the real story is who profits from this microbial revolution in dementia research.
Forget slow R&D. AI-designed enzymes are here, promising hyper-efficient industrial chemistry. But who truly controls this molecular fast-track?